文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

单份UM171扩增脐带血造血干细胞移植:单臂1-2期安全性与可行性研究

Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
PubMed 文献 · Lancet Haematol · 2019-11-06

这项在加拿大两中心开展的单臂1-2期研究,评估单份UM171扩增脐带血移植用于无合适HLA匹配供者血液肿瘤患者的安全性与可行性。

要点

  • UM171扩增成功26/27份脐带血(96%),单份移植后无移植失败。
  • 常见非血液学不良事件为3级发热性中性粒细胞减少(73%)和菌血症(41%)。

核心结论

  • 初步结果表明UM171脐带血干细胞扩增可行、安全,允许使用小份单脐带血而不影响 engraftment。
  • UM171扩增脐带血可能克服其他脐带血移植的缺点,同时保持慢性GVHD和复发风险低的优势,值得随机试验进一步研究。

研究设计与样本

  • 单臂、开放标签、1-2期安全性与可行性研究,在加拿大两家医院开展。
  • 研究分两部分:第一部分用两份脐带血(一份UM171扩增、一份未处理)直至扩增脐带血 engraftment;第二部分为单份UM171扩增脐带血移植,采用剂量递减设计确定最小细胞剂量。
  • 纳入标准:年龄3-64岁、体重≥12 kg、有异基因造血干细胞移植指征的血液肿瘤、无合适HLA匹配供者、Karnofsky评分≥70%。
  • 实际仅两家中心开放且仅治疗成人,未招募儿童患者(<18岁)。
  • 2016年2月17日至2018年11月11日共入组27例,其中4例在第一部分接受两份脐带血;第二部分入组23例,22例接受单份UM171扩增脐带血移植。

主要发现

  • 数据截止2018年12月31日,中位随访18个月(IQR 12-22)。
  • 成功用UM171扩增26/27份脐带血(96%)。
  • 血小板恢复中位42天(IQR 35-47)。
  • 最常见非血液学不良事件为3级发热性中性粒细胞减少(16/22,73%)和菌血症(9/22,41%);未观察到意外不良事件;1/22(5%)死于治疗相关弥漫性肺泡出血。

关键数值与推荐

  • 清髓性预处理(<50岁无合并症):环磷酰胺120 mg/kg、氟达拉滨75 mg/m2、12 Gy全身照射。
  • 减低强度预处理(>50岁或有合并症):环磷酰胺50 mg/kg、塞替派10 mg/kg、氟达拉滨150 mg/m2、4 Gy全身照射。
  • 输注7天UM171扩增的CD34阳性细胞及含淋巴细胞的CD34阴性组分。

临床怎么用

  • 对于无合适HLA匹配供者的血液肿瘤患者,单份UM171扩增脐带血移植可能是可行选择,允许使用较小份脐带血。
  • 需关注发热性中性粒细胞减少和菌血症等感染性不良事件,以及治疗相关弥漫性肺泡出血风险。
  • 目前证据来自单臂1-2期研究,应在随机试验中进一步验证后方可常规推广。

局限性

  • 单臂、开放标签设计,无对照组。
  • 仅两家中心开放且仅治疗成人,未招募儿童患者。
  • 样本量小(单份移植22例),随访时间有限(中位18个月)。
  • 计划五家中心参与但仅两家开放,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Benefits of cord blood transplantation include low rates of relapse and chronic graft-versus-host disease (GVHD). However, the use of cord blood is rapidly declining because of the high incidence of infections, severe acute GVHD, and transplant-related mortality. UM171, a haematopoietic stem cell self-renewal agonist, has been shown to expand cord blood stem cells and enhance multilineage blood cell reconstitution in mice. We aimed to investigate the safety and feasibility of single UM171-expanded cord blood transplantation in patients with haematological malignancies who do not have a suitable HLA-matched donor. METHODS: This single-arm, open-label, phase 1-2 safety and feasibility study was done at two hospitals in Canada. The study had two parts. In part 1, patients received two cord blood units (one expanded with UM171 and one unmanipulated cord blood) until UM171-expanded cord blood demonstrated engraftment. Once engraftment was documented we initiated part 2, reported here, in which patients received a single UM171-expanded cord blood unit with a dose de-escalation design to determine the minimal cord blood unit cell dose that achieved prompt engraftment. Eligible patients were aged 3-64 years, weighed 12 kg or more, had a haematological malignancy with an indication for allogeneic hematopoietic stem cell transplant and did not have a suitable HLA-matched donor, and a had a Karnofsky performance status score of 70% or more. Five clinical sites were planned to participate in the study; however, only two study sites opened, both of which only treated adult patients, thus no paediatric patients (aged <18 years) were recruited. Patients aged younger than 50 years without comorbidities received a myeloablative conditioning regimen (cyclophosphamide 120 mg/kg, fludarabine 75 mg/m2, and 12 Gy total body irradiation) and patients aged older than 50 years and those with comorbidities received a less myeloablative conditioning regimen (cyclophosphamide 50 mg/kg, thiotepa 10 mg/kg, fludarabine 150 mg/m2, and 4 Gy total body irradiation). Patients were infused with the 7-day UM171-expanded CD34-positive cells and the lymphocyte-containing CD34-negative fraction. The primary endpoints were feasibility of UM171 expansion, safety of the transplant, kinetics of hematopoietic reconstitution (time to neutrophil and platelet engraftment) of UM171-expanded cord blood, and minimal pre-expansion cord blood unit cell dose that achieved prompt engraftment. We analysed feasibility in all enrolled patients and all other primary outcomes were analysed per protocol, in all patients who received single UM171-expanded cord blood transplantation. This trial has been completed and was registered with ClinicalTrials.gov, NCT02668315. FINDINGS: Between Feb 17, 2016, and Nov 11, 2018, we enrolled 27 patients, four of whom received two cord blood units for safety purposes in part 1 of the study. 23 patients were subsequently enrolled in part 2 to receive a single UM171-expanded cord blood transplant and 22 patients received a single UM171-expanded cord blood transplantation. At data cutoff (Dec 31, 2018), median follow-up was 18 months (IQR 12-22). The minimal cord blood unit cell dose at thaw that achieved prompt engraftment as a single cord transplant after UM171 expansion was 0·52 × 105 CD34-positive cells. We successfully expanded 26 (96%) of 27 cord blood units with UM171. Among the 22 patients who received single UM171-expanded cord blood transplantation, median time to engraftment of 100 neutrophils per μL was 9·5 days (IQR 8-12), median time to engraftment of 500 neutrophils per μL was 18 days (12·5-20·0), and no graft failure occurred. Median time to platelet recovery was 42 days (IQR 35-47). The most common non-haematological adverse events were grade 3 febrile neutropenia (16 [73%] of 22 patients) and bacteraemia (nine [41%]). No unexpected adverse events were observed. One (5%) of 22 patients died due to treatment-related diffuse alveolar haemorrhage. INTERPRETATION: Our preliminary findings suggest that UM171 cord blood stem cell expansion is feasible, safe, and allows for the use of small single cords without compromising engraftment. UM171-expanded cord blood might have the potential to overcome the disadvantages of other cord blood transplants while maintaining the benefits of low risk of chronic GVHD and relapse, and warrants further investigation in randomised trials. FUNDING: Canadian Institutes of Health Research, Canadian Cancer Society and Stem Cell Network.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Cohen S, Roy J, Lachance S, et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 2019. PMID: 31704264. doi:10.1016/S2352-3026(19)30202-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。